Key Details
Price
$7.40PE Ratio
148.00Annual ROE
339.11%Beta
1.27Events Calendar
Next earnings date:
Jan 10, 2025Recent quarterly earnings:
Oct 04, 2024Recent annual earnings:
Aug 26, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
CHASKA, Minn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it hosted a virtual investor day prior to market open during which Lifecore's senior management team discussed the company's business and strategy for growth in the future, among other topics. A replay of the event is available via webcast and can be accessed by visiting the Events & Presentations section of Lifecore's investor web page at: https://ir.lifecore.com/events-presentations.
CHASKA, Minn., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will host a virtual investor day on Thursday, November 21, 2024, prior to market open. The event will take place from 8:00 – 9:30 a.m. Eastern Time and be available via webcast. During the event, members of Lifecore's senior management team will discuss the company's business and strategy for growth in the future, among other topics.
SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary duties to the company and its shareholders.
-- Recorded Revenues of $24.7 Million for Q1 Fiscal 2025 -- -- Signed Multiple New Business Agreements with New and Existing Customers --
PIPE with New and Existing Investors Supports Working Capital and Operations PIPE with New and Existing Investors Supports Working Capital and Operations
CHASKA, Minn., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the first quarter of fiscal year 2025 on Friday, October 4, 2024, prior to market open and will host a webcast at 8:30 a.m. Eastern Time. Members of Lifecore's senior management team will discuss financial results for the first quarter and review recent corporate developments.
Multi-Million Dollar Development Agreement Establishes Lifecore as Lindy Biosciences' Preferred CDMO
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR) and certain of its officers.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESSWIRE / September 27, 2024 / If you suffered losses exceeding $75,000 in Lifecore between October 7, 2020 and March 19, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and reminds investors of the September 27, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
FAQ
- What is the primary business of Lifecore Biomedical?
- What is the ticker symbol for Lifecore Biomedical?
- Does Lifecore Biomedical pay dividends?
- What sector is Lifecore Biomedical in?
- What industry is Lifecore Biomedical in?
- What country is Lifecore Biomedical based in?
- When did Lifecore Biomedical go public?
- Is Lifecore Biomedical in the S&P 500?
- Is Lifecore Biomedical in the NASDAQ 100?
- Is Lifecore Biomedical in the Dow Jones?
- When was Lifecore Biomedical's last earnings report?
- When does Lifecore Biomedical report earnings?
- Should I buy Lifecore Biomedical stock now?